Prochlorperazine Maleate NDC 70710-1668

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1668Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1668Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1668-1	70710166801	100 TABLET in 1 BOTTLE (70710-1668-1)Marketed from Aug 10, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Prochlorperazine Maleate
Generic name (nonproprietary): prochlorperazine maleate
Active ingredients: Prochlorperazine maleate — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Zydus Pharmaceuticals (USA) Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216495
Marketing start: Aug 10, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Phenothiazines (Chemical structure)
Identifiers: Product ID 70710-1668_da187256-50af-400b-ab27-a073f3fbe81aSPL ID da187256-50af-400b-ab27-a073f3fbe81aSPL set ID d4a34138-a01b-418f-8e0f-e81f6e1cfd89RxCUI 198365, 312635UNII I1T8O1JTL6
Pharmacologic class: Phenothiazine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710166801 followed by a unit qualifier and the quantity

Package 70710-1668-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 15, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 216495

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216495
Product	Strength	Form · route	Labeler	Product NDC
Prochlorperazine Maleate	Prochlorperazine maleate 5 mg/1	TabletOral	Zydus Pharmaceuticals (USA) Inc.	70710-1667
Prochlorperazine Maleate	Prochlorperazine maleate 10 mg/1	TabletOral	Northwind Health Company, LLC	82868-044
Prochlorperazine Maleate	Prochlorperazine maleate 5 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1697
Prochlorperazine Maleate	Prochlorperazine maleate 10 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1698
Prochlorperazine Maleate	Prochlorperazine maleate 10 mg/1	TabletOral	REMEDYREPACK INC.	70518-4200